Highly purified single-chain factor VII was isolated from plasma and used to generate monospecific antibodies. A double-antibody equilibrium radioimmunoassay was constructed. The assay was tested for and met all the criteria required for a specific, sensitive, and accurate determination of factor VII in plasma. The range of sensitivity of the assay was between 1 and 500 ng factor VII/ml, and th...

FEIBA and Autoplex T have been used to control bleeding in patients with factor VIII or IX inhibitors for over 25 years. The major components of FEIBA are thought to be activated factor X and prothrombin, whereas the main active components in Autoplex T are thought to be activated factors IX and VII. Both products have been found to effectively control approximately 80% of bleeds involving join...

One pathway of blood coagulation, the extrinsic system, is initiated by a specific interaction between tissue factor, which is a membrane lipoprotein, and factor VII, one of the plasma coagulation factors. Factor VII was prepared from bovine plasma by adsorption onto and elution from BaSO(4). The eluate was chromatographed on DEAE-Sephadex and purified by preparative disc-gel electrophoresis. F...

By S00NA S. SETNA .-5’NI) S. J. ALTMAN I T IS \VELL KNO\VX that deficiencies of prothrombimi and proconvertin can I)e the cause of serious bleedimig.’’ In addition to recognized causes of these deficiencies, su(’h as inadequate imitake, aI)sorption or utilization of vitamin K, cases of unrecognized cause may be emicountered.6 To date, an acquired idiopathic deficiency of these two sul)stamices ...

Transfusion of platelet concentrates remains the first-line therapy for Glanzmann thrombasthenia in case of bleeding or preparation for surgery. However, development of antibodies to platelet glycoprotein (Gp) IIb/IIIa complex or human leukocyte antigens (HLA) is frequent and the main cause of platelet refractoriness. Recombinant activated factor VII (rFVIIa) is a potent alternative for patient...

Bleeding remains a potential complication for patients requiring extracorporeal life support systems. Recombinant activated factor VII (rFVIIa) is one of the drugs used in controlling bleeding. Its use is generally found to be safe. We report a paediatric patient who developed fatal thrombosis with the use of rFVIIa whilst on extracorporeal membrane oxygenation and discuss the possible factors ...